Literature DB >> 16328197

[Prophylactic thyroid surgery].

A Frilling1, F Weber.   

Abstract

Early diagnosis for thyroid carcinoma, potentially before neoplastic transformation has taken place, would allow preventive and thus curative surgical intervention. Identifying and characterizing the RET proto-oncogene as the disease-causing gene for hereditary medullary thyroid carcinoma and then establishing a genotype-phenotype correlation served as the prerequisite for the risk-adapted prophylactic surgical approach practised today. Carriers of RET mutations associated with very aggressive tumour behaviour should be subjected to prophylactic thyroidectomy within the 1st year of life. For individuals harbouring less virulent types of mutations, prophylactic intervention is recommended at 5-20 years. Although genetic research on hereditary nonmedullary thyroid cancer is still in progress, initial results indicate the need of prophylactic surgical treatment also for this subgroup of thyroid neoplasia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16328197     DOI: 10.1007/s00104-005-1118-7

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  34 in total

Review 1.  Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease.

Authors:  C Eng
Journal:  N Engl J Med       Date:  1996-09-26       Impact factor: 91.245

2.  Activation of a novel human transforming gene, ret, by DNA rearrangement.

Authors:  M Takahashi; J Ritz; G M Cooper
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

Review 3.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

Review 4.  Management of patients with hereditary medullary thyroid carcinoma.

Authors:  G Fitze
Journal:  Eur J Pediatr Surg       Date:  2004-12       Impact factor: 2.191

Review 5.  Highly penetrant hereditary cancer syndromes.

Authors:  Rebecca Nagy; Kevin Sweet; Charis Eng
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

6.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

7.  Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage.

Authors:  N E Simpson; K K Kidd; P J Goodfellow; H McDermid; S Myers; J R Kidd; C E Jackson; A M Duncan; L A Farrer; K Brasch
Journal:  Nature       Date:  1987 Aug 6-12       Impact factor: 49.962

8.  Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease.

Authors:  T Attié; A Pelet; P Edery; C Eng; L M Mulligan; J Amiel; L Boutrand; C Beldjord; C Nihoul-Fékété; A Munnich
Journal:  Hum Mol Genet       Date:  1995-08       Impact factor: 6.150

Review 9.  Gene-expression profiling in differentiated thyroid cancer--a viable strategy for the practice of genomic medicine?

Authors:  Frank Weber; Charis Eng
Journal:  Future Oncol       Date:  2005-08       Impact factor: 3.404

10.  Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.

Authors:  A Frilling; H Dralle; C Eng; F Raue; C E Broelsch
Journal:  Surgery       Date:  1995-12       Impact factor: 3.982

View more
  1 in total

Review 1.  Personalized medicine: caught between hope, hype and the real world.

Authors:  Marc Dammann; Frank Weber
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.